April 25 (Reuters) - Sanofi's Sasy.pa Said on Thursday First-Quarter Operating Income Declined 14.7% as Unfavourable Currency Effects and Cheap Competition to Multiple Sclerosis Drug Aubagio Outweighed Rising Sales of Anti-Inflammatory Drug Dupixent.
4月25日（路透社）——賽諾菲 Sasy.pa 週四表示，由於不利的貨幣影響和對多發性硬化症藥物Aubagio的廉價競爭超過了抗炎藥物Dupixent的銷售增長，第一季度營業收入下降了14.7％。
The French Drugmaker Said in a Statement That Operating Income, Adjusted for One-Offs, Slipped 14.7% to 2.84 Billion Euros ($3.04 Billion), a Touch Above the 2.79 Billion Euros Expected on Average by Analysts in a Poll on the Company's Website.
這家法國製藥商在一份聲明中表示，經一次性調整後的營業收入下降了14.7％，至28.4億歐元（合30.4億美元），略高於分析師在該公司網站上進行的一項民意調查中預期的平均27.9億歐元。
The Company Reiterated It Expects 2024 Adjusted Earnings per Share (EPS) to Slip by a "Low Single-Digit" Percentage, Excluding Currency Swings, Citing Higher Taxes and an Increase in Development Expenditure.
該公司重申，預計2024年調整後的每股收益（EPS）將下降 “較低的個位數” 百分比，其中不包括貨幣波動，理由是稅收增加和發展支出增加。
Currency Changes Would Drag 2024 Earnings Lower by Between 5.5% and 6.5% at Current Rates, It Added.
它補充說，按當前利率計算，貨幣變化將使2024年的收益下降5.5％至6.5％。
($1 = 0.9338 Euros)
（$1 = 0.9338 歐元）
(Reporting by Ludwig Burger; Editing by Benoit Van Overstraeten)
（路德維希·伯格報道；Benoit Van Overstraeten編輯）
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))